Clinical Trials Results
Results for the search you initiated will be displayed below.
Trial Name
Brief Summary
This randomized phase III trial studies how well initial treatment with ipilimumab and
nivolumab followed by dabrafenib and trametinib works and compares it to initial treatment
with dabrafenib and trametinib followed by ipilimumab and nivolumab in treating patients with
stage III-IV melanoma that contains a mutation known as BRAFV600 and cannot be removed by
surgery (unresectable). Immunotherapy with monoclonal antibodies, such as ipilimumab and
nivolumab, may help the body's immune system attack the cancer, and may interfere with the
ability of tumor cells to grow and spread. Dabrafenib and trametinib may block tumor growth
by targeting the BRAFV600 gene. It is not yet known whether treating patients with ipilimumab
and nivolumab followed by dabrafenib and trametinib is more effective than treatment with
dabrafenib and trametinib followed by ipilimumab and nivolumab.
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given
together with or without sargramostim and to see how well they work in treating patients with
stage III-IV melanoma that cannot be removed by surgery (unresectable). Immunotherapy with
monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system
attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Colony-stimulating factors, such as sargramostim, may increase the production of white blood
cells. It is not yet known whether nivolumab and ipilimumab are more effective with or
without sargramostim in treating patients with melanoma.
This phase II trial studies how well encorafenib and binimetinib work before surgery in
treating patients with BRAF V600-mutated stage IIIB-D melanoma that has spread to the lymph
nodes. Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. This trial also studies how well 18F-FLT positron emission
tomography (PET)/computed tomography (CT) works in predicting the response of melanoma to
encorafenib and binimetinib. 18F-FLT is an imaging agent, sometimes called a tracer. PET and
CT are types of imaging scans. Using 18F-FLT PET/CT together with encorafenib and binimetinib
may provide more information on melanoma over time.
This pilot phase II trial studies how well pembrolizumab works in treating patients with
desmoplastic melanoma (DM) that can or cannot be removed by surgery (unresectable).
Monoclonal antibodies, like pembrolizumab, may block specific proteins which may strengthen
the immune system and control tumor growth.
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus
ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread
to the brain (brain metastases). Encorafenib and binimetinib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. Ipilimumab and nivolumab are
monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread.
This trial aims to find out which approach is more effective in shrinking and controlling
brain metastases from melanoma.
Clinical Trial Categories:
- Bone Cancer
- Brain Cancer
- Breast Cancer
- Cancer Control
- Companion Studies
- Gastrointestinal Cancer
- Genitourinary Cancer
- Gynecology (GYN) Cancer
- Head and Neck Cancer
- Leukemia
- Lung Cancer
- Lymphoma (Hodgkin's Disease, Non-Hodgkin's Lymphoma)
- Melanoma
- Multiple Myeloma
- Myelodysplastic Syndrome (MDS)
- Other Cancer Protocols
- Pancreas Cancer
- Sarcoma
- Skin Cancer
- Symptom Management